BCL2L10
BCL2 Like 10, Apoptosis Regulator
Gene Information Card
| Symbol | BCL2L10 |
|---|---|
| Full Name | BCL2 Like 10 |
| Gene Type | protein-coding |
| Chromosomal Location | 15q21.2 |
| NCBI Gene ID | 10017 ncbi.nlm.nih.gov/gene/10017 |
| Ensembl ID | ENSG00000137868 |
| UniProt ID | Q9HD36 |
| OMIM ID | 606910 |
| HGNC ID | 993 |
| Aliases | Bcl-B, Boo, Diva |
Description
BCL2L10 (BCL2 Like 10) is a protein-coding gene belonging to the BCL-2 family of apoptosis regulators. The encoded protein contains conserved BCL-2 homology domains (BH1, BH2, BH3, BH4) and a transmembrane domain. It can both promote and inhibit apoptosis depending on cellular context, and is involved in mitochondrial membrane permeabilization and caspase activation.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast Cancer | Overexpression of BCL2L10 inhibits apoptosis, promoting tumor cell survival | PMID: 15626733 |
| Lung Cancer | Altered expression linked to chemoresistance via anti-apoptotic function | PMID: 19137017 |
| Colorectal Cancer | Upregulation associated with poor prognosis and resistance to therapy | PMID: 21804532 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 12.5 | Medium |
| Bone Marrow | 8.3 | Low |
| Lymph Node | 6.1 | Low |
| Breast | 4.7 | Low |
| Lung | 3.2 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (Breast Cancer) | 15.2 | Moderate expression |
| A549 (Lung Cancer) | 9.8 | Low expression |
| HEK293 (Embryonic Kidney) | 5.4 | Low expression |
| K562 (Leukemia) | 2.1 | Not detected |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1Val) | Missense | <0.1% | Potential loss of start codon, reduced protein expression |
| c.100C>T (p.Arg34Trp) | Missense | <0.1% | Unknown functional effect |
| c.200_201insA | Frameshift | <0.1% | Predicted loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations that truncate the protein or disrupt BH domains are predicted to cause loss of anti-apoptotic function.
Gain of Function (GOF)
Missense mutations that enhance stability or dimerization with pro-apoptotic partners may confer gain-of-function, but evidence is limited.
Dominant Negative (DN)
Mutations that disrupt BH3 binding but retain dimerization could act as dominant-negative inhibitors of wild-type BCL2L10.
View complete mutation data：
Gene Ontology (GO)
| • apoptotic process (GO:0006915) | • intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630) |
| • negative regulation of apoptotic process (GO:0043066) | • mitochondrion (GO:0005739) |
| • integral component of membrane (GO:0016021) | • identical protein binding (GO:0042802) |
Pathways
• Apoptosis - Homo sapiens (human) (KEGG: hsa04210)
• Intrinsic Pathway for Apoptosis (Reactome: R-HSA-109606)
Protein Summary
BCL2L10 (Bcl-B) is a 204-amino acid protein with a molecular weight of approximately 23 kDa. It localizes to the mitochondrial outer membrane and contains BH1, BH2, BH3, and BH4 domains. BCL2L10 can heterodimerize with pro-apoptotic BCL-2 family members such as BAX and BAK, inhibiting their pro-apoptotic function. It also interacts with BCL2L11 (BIM) and BID. The protein is expressed in testis, bone marrow, and lymphoid tissues, and its overexpression in various cancers contributes to chemoresistance.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| BCL2L10 Knockout HEK293 Cell Line | EDJ-KQ6864 | Human | 10017 | Details Get a Quote |
| BCL2L10 Knockout HeLa Cell Line | EDJ-KQ55300 | Human | 10017 | Details Get a Quote |
| BCL2L10 Knockout A-549 Cell Line | EDJ-KQ63782 | Human | 10017 | Details Get a Quote |
| BCL2L10 Knockout HCT 116 Cell Line | EDJ-KQ72240 | Human | 10017 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
